Condensed Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Beginning balance (in shares) at Dec. 31, 2023		24,554,000
Beginning balance at Dec. 31, 2023	$ 105,195	$ 2	$ 374,129	$ 27	$ (268,963)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	3,589		3,589
Unrealized loss on investments, net of tax	(35)			(35)
Net income (loss)	(18,289)				(18,289)
Ending balance (in shares) at Mar. 31, 2024		24,554,000
Ending balance at Mar. 31, 2024	$ 90,460	$ 2	377,718	(8)	(287,252)
Beginning balance (in shares) at Dec. 31, 2024	24,680,708	24,681,000
Beginning balance at Dec. 31, 2024	$ 52,478	$ 2	385,114	16	(332,654)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense	$ 1,680		1,680
Issuance of common stock upon exercise of warrants (in shares)		426,000
Issuance of common stock upon exercise of stock options (in shares)	22,204	22,000
Issuance of common stock upon exercise of stock options	$ 21		21
Issuance of common stock in conjunction with vesting of restricted stock units (in shares)		63,000
Private placement, net of transaction costs (in shares)		21,592,000
Private placement, net of transaction costs	94,548	$ 2	94,546
Unrealized loss on investments, net of tax	(15)			(15)
Net income (loss)	$ 73,016				73,016
Ending balance (in shares) at Mar. 31, 2025	46,784,618	46,784,000
Ending balance at Mar. 31, 2025	$ 221,728	$ 4	$ 481,361	$ 1	$ (259,638)